Regenxbio
RGNX
182 hedge funds and large institutions have $927M invested in Regenxbio in 2022 Q3 according to their latest regulatory filings, with 30 funds opening new positions, 65 increasing their positions, 59 reducing their positions, and 12 closing their positions.
200% more funds holding in top 10
Funds holding in top 10: 1 → 3 (+2)
150% more first-time investments, than exits
New positions opened: 30 | Existing positions closed: 12
23% more call options, than puts
Call options by funds: $2.8M | Put options by funds: $2.27M
10% more funds holding
Funds holding: 165 → 182 (+17)
10% more repeat investments, than reductions
Existing positions increased: 65 | Existing positions reduced: 59
3% more capital invested
Capital invested by funds: $896M → $927M (+$30.9M)
2.78% less ownership
Funds ownership: 83.9% → 81.12% (-2.8%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MB
MPM BioImpact
Boston,
Massachusetts
|
+$18.4M |
| 2 |
Dimensional Fund Advisors
Austin,
Texas
|
+$5.24M |
| 3 |
Goldman Sachs
New York
|
+$3.89M |
| 4 |
MPAM
Monarch Partners Asset Management
Boston,
Massachusetts
|
+$2.95M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$2.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SI
Sofinnova Investments
Menlo Park,
California
|
-$16.7M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$16.3M |
| 3 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$8.97M |
| 4 |
RCMNY
Rubric Capital Management (New York)
New York
|
-$7.1M |
| 5 |
ACM
Aquilo Capital Management
San Francisco,
California
|
-$5.93M |
RGNX Hedge Fund Activity: Q3 2022 in Review
182 of the 5,828 institutional investors tracked by Wall St. Rank reported a position in Regenxbio (RGNX) for Q3 2022, worth a combined $927M — up 3.4% from $896M a quarter earlier.
Buyers outnumbered sellers: 30 funds opened new RGNX positions and 12 closed out — a net gain of 18 holders — while 65 added to existing stakes and 59 trimmed.
The largest buyer was MPM BioImpact, opening a new position worth an estimated $18.4M. The largest seller was Sofinnova Investments, cutting an estimated $16.7M.
- 182 institutional investors held Regenxbio (RGNX) as of Q3 2022, up from 165 in Q2 2022.
- Funds reported $927M of Regenxbio stock for Q3 2022, up 3.4% quarter-over-quarter.
- 30 funds opened new Regenxbio positions in Q3 2022 and 12 closed out, a net change of +18 holders.
- The largest Regenxbio buyer in Q3 2022 was MPM BioImpact, an estimated $18.4M added.
- The largest Regenxbio seller in Q3 2022 was Sofinnova Investments, an estimated $16.7M sold.
Based on aggregated 13F filings for Q3 2022.